Acasti Pharma is a biopharmaceutical company based in Canada. Co. is engaged in the research, development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment and prevention of cardiovascular disorders. Co.'s products are derived from krill oil. Co.'s products include: CaPre® is for prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia; and Onemia™ is for cardiometabolic disorders treatments. Co. sells its products primarily in Canada and the U.S. We show 4 historical shares outstanding datapoints in our coverage of ACST's shares outstanding history.
Understanding the changing numbers of ACST shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACST versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACST by allowing them to research ACST shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
